METTL7A Downregulation Drives SLC1A5‐Mediated Glutamine Competition to Promote Tumor Proliferation and Suppress CD8 + T Cell Immunity in Gastric Cancer
Open Access
- 3 August 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 13 (60) , e76963
Abstract
Tumor metabolic dysregulation is a critical determinant of tumor progression and response to immunotherapy. Aberrant glutamine metabolism is a hallmark of gastric cancer (GC). However, beyond fueling GC cell anabolism, its role in remodeling the immunosuppressive tumor microenvironment remains poorly understood. Here, we show that GC cells overexpress solute carrier family 1 member 5 (SLC1A5) to drive glutamine accumulation, which not only promotes their own proliferation but also reduces glutamine availability to CD8 + T cells, thereby suppressing antitumor immunity. These dual effects cooperatively drive GC progression. Mechanistically, loss of methyltransferase‐like protein 7A (METTL7A) stabilizes SLC1A5 mRNA by reducing its m6A modification. Concurrently, METTL7A deficiency increased N‐glycosyltransferase β‐1,4‐galactosyltransferase 5 (B4GALT5) expression. B4GALT5 stabilizes SLC1A5 via N‐glycosylation at the N212 site, which blocks K48‐linked polyubiquitination and proteasomal degradation. We identify the natural flavonoid luteolin as an agent that upregulates METTL7A expression, which subsequently downregulates SLC1A5 expression and inhibits GC progression. Furthermore, luteolin significantly enhances the efficacy of anti‐PD‐1 therapy in GC. Collectively, our findings reveal that SLC1A5‐mediated glutamine competition drives both tumor cell proliferation and immune evasion in GC, and suggest that targeting the METTL7A/SLC1A5 axis may represent a promising therapeutic strategy.Keywords
This publication has 33 references indexed in Scilit:
- HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancerCell Metabolism, 2025
- m6A alters ribosome dynamics to initiate mRNA degradationCell, 2025
- Paclitaxel/Luteolin Coloaded Dual‐Functional Liposomes for Esophageal Cancer TherapyAdvanced Science, 2025
- Blocking ITGA5 potentiates the efficacy of anti‐PD‐1 therapy on glioblastoma by remodeling tumor‐associated macrophagesCancer Communications, 2025
- Inhibition of Mettl3 ameliorates osteoblastic senescence by mitigating m6A modifications on Slc1a5 via Igf2bp2-dependent mechanismsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cellsCell, 2024
- The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemiaCancer Cell, 2022
- Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancerCell Metabolism, 2022
- Succinate receptor 1 inhibits mitochondrial respiration in cancer cells addicted to glutamineCancer Letters, 2022
- N-linked Glycosylation of human SLC1A5 (ASCT2) transporter is critical for trafficking to membraneBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2015